Clinical Trial Search

Primary: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay — -47.35; -81.57; -85.71; 0.48 Percent change — p=<.001

Primary: Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16 — -5.31; -8.31 percent change — p=0.18

Primary: Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging — 0.47; -0.16 ratio — p=0.001

Primary: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 — -39.0; -74.4; -93.7; 3.1 percent change — p=<0.001

Primary: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 5; 3; 3; 5 Participants

Primary: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 — -80.5; -79.1; -83.3; 2.3 Percentage — p=<0.0001

Primary: Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point — -35; -56; -72; -58 percent change — p=0.0032

Primary: Percent Change From Baseline in Lipoprotein Lp(a) Plasma Concentration at Day 85/Day 99 — -3.7; -44.5; -70.0; -5.6 percent change — p=<.001

Primary: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 — -66.91; -93.78; -97.53; -96.89 Percentage Change in Lp(a) — p=<0.001

Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml

Primary: Maximum Observed Concentration (Cmax) of Olpasiran — 144; 549 ng/mL

Primary: Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries — 7; 5 percentage of internal…

Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…

Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018

Primary: Brachial Artery Flow-mediated Dilation (FMD) — 12.0; 9.8; 10.4; 10.2 % change in brachial artery diameter — p=0.58

Primary: Postprandial Incremental Area Under the Curve From 0-6 Hours (iAUC)[0-6] of Apolipoprotein B-48 (ApoB-48) — 63.4; 41.7 μg/mL x h — p=0.0078

Primary: Occurence of Death — 1; 1; 1; 1 participants

Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05

Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants

Primary: Myocardial Perfusion at Rest — 55; 135 IU/s

Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001

Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change

Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid

Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml

Primary: Percentage Change in Coronary Artery Diameter — 3; 3 % change coronary artery diameter

Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001

Primary: Number of Participants With 1 or More Drug Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAEs) — 4; 3; 5; 2 Participants

Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL

Primary: L5 Concentration in Metabolic Syndrome Patients — 35.97; 17.8233; 29.736; 23.1 mg/dL

Primary: Cmax for Lomitapide — 0.570; 0.436; 1.70; 1.01 ng/mL